key: cord-0809737-gzh6oxg6 authors: Boonyawat, Kochawan; Angchaisuksiri, Pantep title: Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia date: 2022-01-15 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12644 sha: 660a1710f90e0cdd2e7d59dc890f80123ea2c978 doc_id: 809737 cord_uid: gzh6oxg6 BACKGROUND: Vaccination with ChAdOx1 n‐CoV‐19 is associated with a rare syndrome called vaccine‐induced immune thrombotic thrombocytopenia (VITT). VITT has been reported mainly in Western countries, whereas the report of VITT in Asians is sparse. OBJECTIVES: To report a case series of VITT following ChAdOx1 n‐CoV‐19 in Thailand and to estimate the incidence of VITT among Asian countries. METHODS: We retrieved the number of VITT patients and the total inoculation doses from the database of the Thai Ministry of Public Health. We performed a literature search including published articles and gray literature to estimate the incidence of VITT. The incidences of VITT by countries and respective confidence intervals were calculated. RESULTS: By the end of August 2021, five VITT cases occurred after 15 million doses of ChAdOx1 n‐CoV‐19 in Thailand. The median age was 31 years, and 60% were women. The incidence of VITT is estimated at 1 in 3 million. In other Asian countries, only a few cases of VITT have been reported. The incidence of VITT is much lower than in those of Western countries, which is estimated at 1 in 100, 000. The fatality rate was 44% in this study. CONCLUSIONS: Although the incidence of VITT in Asians is low, the mortality rate is substantially higher. We urge that public awareness of this syndrome be raised, as early recognition and appropriate treatment of this syndrome following ChAdOx1 n‐CoV‐19 are crucial to improve the outcome. We retrieved the number of VITT cases and the total number of inoculations from the database of the Thai Ministry of Public Health. We performed a literature search including published articles and gray literature to estimate the incidence of VITT. Baseline characteristics of patients with VITT in Thailand and South Korea were summarized using descriptive statistics. The incidences of VITT by countries and respective confidence intervals were estimated from the reported incidences and the standard errors of proportion. All statistical analyses were performed using Stata software version 16 (StataCorp, College Station, TX, USA). At the end of August 2021, there were five cases of VITT reported in Thailand (Table 1) . We classified the definition of VITT according to the proposed criteria. 5 All five criteria, including timing, thrombosis, thrombocytopenia, D-dimer level >4,000 ng/mL fibrinogen equivalent units (FEU), and positive anti-platelet factor 4 (PF4)/polyanionic antibodies, are required for the diagnosis of definite VITT. If D-dimer level was >4,000 ng/mL FEU but one of the other four criteria was absent, the diagnosis of probable VITT was made. If D-dimer level was unknown or in the range of 2,000 to 4,000 ng/mL FEU with one other criterion absent, or two other criteria (timing, thrombosis, thrombocytopenia, or anti-PF4/polyanionic antibodies) were not met, the diagnosis of possible VITT was made. One of our cases was thus classified as definite VITT, two cases were labeled probable, and two were designated possible VITT. A man in his 30s presented with progressive headache and back pain A woman in her 20s presented with progressive headache and vomiting 6 days after the first dose of ChAdOx1 nCoV-19. CT of the brain revealed cerebral sinus thrombosis with intracranial hemorrhage. Her initial platelet count was 192 × 10 9 /L, with a subsequent nadir of 100 × 10 9 /L. D-dimer level was 87, 536 ng/mL FEU. Anti-PF4/polyanionic antibodies were negative, with an OD of 0.2. Given the elevated D-dimer and the fact that one criterion (anti-PF4/polyanionic antibodies) was absent, the patient was classified as probable VITT. She was treated with enoxaparin but later died from brain herniation. A man in his 50s with diabetes, hypertension, and hyperlipidemia He was treated with decompressive craniectomy but, unfortunately, died following brain herniation. A woman in her 70s presented with headache and drowsiness The incidence of VITT is estimated at 1 in 3 million in Thailand. The incidence of VITT in South Korea is estimated at 1 in 6.4 million. 8 The incidence of VITT is estimated at 1 in 0.48 million in Taiwan according to the report from Taiwan's Central Epidemic Command Center. 9,10 VITT occurred in 4 of 2.5 million doses given in Malaysia (Selvaratnam V., personal communication, September 8, 2021). The incidence of VITT reported in Asians is much lower than those in White persons (Figure 1 ). The incidence of VITT is estimated at 1 in 20, 000 to 1 in 50, 000 in the younger population (aged <50 years), while the incidence is ≈1 in 100, 000 in the older population (aged >50 years). 5, 12 Given the rarity of VITT in Asia, we hypothesize that the Asian population is less susceptible to the development of VITT than those in the White population. Of relevance, a lower incidence of HIT in Asian patients compared to White patients has also been reported. 13 The exact mechanism of VITT is still under investigation. However, given the clinical picture of thrombosis and thrombocytopenia with positive anti-PF4/polyanionic antibodies, the clinical picture bears some resemblance to HIT. Heparin can form a complex with PF4 released from platelets. This complex induces autoantibodies that cause intense platelet activation, resulting in thrombocytopenia and thrombosis. While HIT requires heparin as a trigger, VITT does not. This has been described as being analogous to the syndrome of "spontaneous HIT." 14 In VITT, the vaccine itself and/ or its effect upon the host is assumed to be the trigger. It has been variously hypothesized that vaccine constituents form antigenic complexes with PF4, that EDTA in the vaccine induces microvascular permeability, and that vaccine components cause acute inflammatory reactions. Any or all of these mechanisms may promote strong platelet activation and cause the VITT prothrombotic response. 15 Cerebral venous sinus thrombosis is the most common clinical presentation in patients with VITT. An increase in the incidence of cerebral sinus thrombosis after the vaccination compared to the general population has also been observed. 16, 17 The predilection for the cerebral sinus is unclear. One hypothesis is that it may be due to the non-unidirectional blood flow in the cerebral venous sinus that is missing the usual venous valves causing stasis of blood flow. 18 The first case in our cohort presented with severe headache, marked thrombocytopenia, and a markedly elevated D-dimer level but no evidence of cerebral vein thrombosis on MRI and MRV. This could represent a "pre-VITT" syndrome. In a cohort of 11 patients from Germany, 4 patients presented with severe headache that preceded any evidence of thrombosis. All 4 patients developed thrombosis in the 6 to 9 days following the onset of headache. 19 in our cohort had concurrent cerebral sinus thrombosis and intracranial hemorrhage. All patients with intracranial hemorrhage died. This aligned with the finding from the cohort from United Kingdom that intracranial hemorrhage is associated with increased mortality. Our study has a limitation. Since the data were rarely reported, we performed a narrative review of the literature rather than a systematic review. The reporting systems of adverse events are different among Asian countries; thus, the underreporting might be an issue. However, in Thailand, we have three surveillance reporting systems including reports from medical personnel and vaccinees themselves. All serious adverse events after vaccination are reviewed weekly by the National Immunization Center of the Thai Ministry of Public Health. In summary, we report a case series of VITT in Thailand. Current experience suggests a low incidence of VITT in Asians compared to people in Western countries. However, the mortality rate was high. Early diagnosis and appropriate treatment are crucial. We sincerely thank Professor Nigel Key (University of North Carolina at Chapel Hill, USA) for reviewing the manuscript and offering comments. The authors declare no conflicts of interest. KB reviewed literature, analyzed the data, and drafted the manuscript. PA conceived of the study idea and critically revised the manuscript. Pantep Angchaisuksiri @PantepAng Thrombotic thrombocytopenia after ChadOx1 nCoV-19 vaccination Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdox1-A recombinant vaccine Clinical features of vaccineinduced immune thrombocytopenia and thrombosis Brighton Collaboration Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to thrombosis with thrombocytopenia syndrome (TTS) Korea confirms first rare blood clot case linked to AstraZeneca COVID-19 vaccine The Korea Herald2021 Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopenia Taiwanese man in his 30s develops blood clots after AZ shot Taiwan News Taiwan reports another vaccine-induced blood clot case Focus Taiwan Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia Vaccine induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high fatality rate: a case series Low prevalence of heparin-induced thrombocytopenia after cardiac surgery in Thai patients Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia Insights in ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) COVID-19 vaccineassociated cerebral venous thrombosis in Germany Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study Vaccine-induced covid-19 mimicry" syndrome: splice reactions within the SARS-CoV-2 spike open reading frame result in spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines Vaccine-induced thrombocytopenia with severe headache How to cite this article: Boonyawat K, Angchaisuksiri P Vaccine-induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV-19 is rare in Asia